Trial Information
Disease	Metastatic clear cell renal cell carcinoma
Stage of disease/treatment	Metastatic disease/ combination therapy with avelumab and cabozantinib
Prior therapy	None
Type of study	Phase I, 3 + 3
Primary endpoints	To determine the safety of the combined use of avelumab plus cabozantinib and to identify the recommended phase II dose of cabozantinib in patients with mccRCC.
Secondary endpoints	Investigator-assessed confirmed objective response rate, disease control rate, and radiological progression-free survival.
Investigator’s analysis	Active but results were overtaken by other developments